A case of acute pulmonary complication due to botulinum toxin: Patient with central pontine myelinolysis developed acute respiratory distress syndrome after botulinum neurotoxin type A injection into spastic lower extremity muscles.
acute respiratory distress syndrome
botulinum toxin
case report
central pontine myelinolysis
pulmonary complication
thoracic computed tomography
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
revised:
09
07
2023
received:
01
04
2023
accepted:
05
08
2023
medline:
23
10
2023
pubmed:
28
8
2023
entrez:
27
8
2023
Statut:
ppublish
Résumé
Chemodenervation with botulinum neurotoxin type A (BoNTA) is the preferred method for focal spasticity management among various treatment options. While BoNTA injection is considered safe, its widespread use and increasing evidence raise safety concerns. In this paper, we present a patient with central pontine myelinolysis, a rare disease, who developed acute respiratory distress syndrome on the third day after BoNTA application to the spastic gastrocnemius muscle group and required intubation in the intensive care unit due to this complication. To our knowledge, this is the first case reported in the literature to develop an acute pulmonary complication after BoNTA injection into spastic lower extremity muscles.
Substances chimiques
Botulinum Toxins, Type A
EC 3.4.24.69
Neuromuscular Agents
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
3439-3443Informations de copyright
© 2023 The British Pharmacological Society.
Références
Adams RD, Victor M, Mancall EL. Central pontine myelinolysis: A hitherto undescribed disease occurring in alcoholic and malnourished patients. MA Arch Neurol Psychiatr. 1959;81(2):154-172. doi:10.1001/archneurpsyc.1959.02340140020004
Singh TD, Fugate JE, Rabinstein AA. Central pontine and extrapontine myelinolysis: A systematic review. Eur J Neurol. 2014;21(12):1443-1450. doi:10.1111/ene.12571
Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Report of the guideline development Subcommittee of the American Academy of neurology. Neurology. 2016;86:1818-1826.
Rosales RL, Chua-Yap AS. Evidence-based systematic review on the efficacy and safety of botulinum toxin-a therapy in post-stroke spasticity. J Neural Transm. 2008;115(4):617-623. doi:10.1007/s00702-007-0869-3
Andringa A, van de Port I, van Wegen E, Ket J, Meskers C, Kwakkel G. Effectiveness of botulinum toxin treatment for upper limb spasticity after stroke over different ICF domains: A systematic review and meta-analysis. Arch Phys Med Rehabil. 2019;100(9):1703-1725. doi:10.1016/j.apmr.2019.01.016
Francisco GE, Li S. Spasticity. In: Braddom's physical medicine and rehabilitation. 5th ed. Elsevier; 2015.
Sethi N, Singh S, DeBoulle K, Rahman E. A review of complications due to the use of botulinum toxin a for cosmetic indications. Aesthetic Plast Surg. 2021;45(3):1210-1220. doi:10.1007/s00266-020-01983-w
Ramirez-Castaneda J, Jankovic J. Long-term efficacy and safety of botulinum toxin injections in dystonia. Toxins (Basel). 2013;5(2):249-266. doi:10.3390/toxins5020249
Baizabal-Carvallo JF, Jankovic J, Pappert E. Flu-like symptoms following botulinum toxin therapy. Toxicon. 2011;58(1):1-7. doi:10.1016/j.toxicon.2011.04.019
Moore AP. Movement, visceral and autonomic disorders: Use of botulinum toxin. Hospital Med. 2003;64(8):452-459. doi:10.12968/hosp.2003.64.8.2258
Oliver JD, Boesch RP, Mack KJ. Decreased pulmonary function during botulinum toxin a therapy for chronic migraines in a 17-year-old female. Headache: The Journal of Head and Face Pain. 2018;58(8):1259-1261. doi:10.1111/head.13359
Schoene R, Brashear A, Turkel CC, McIntosh R, Liu J, Brin MF. A randomized, double-blind, placebo-controlled, parallel group multicenter study evaluating the effect of botulinum toxin type A treatment on pulmonary function in patients with poststroke focal spasticity. Arch Phys Med Rehabil. 2006;87(11):e10. doi:10.1016/j.apmr.2006.08.054
Taysse L, Daulon S, Calvet JH, et al. Induction of acute lung injury after intranasal administration of toxin botulinum a complex. Toxicol Pathol. 2005;33(3):336-342. doi:10.1080/01926230590922884
Ermert LE, Bruckner HE, Walmrath DI, et al. Role of endothelial cytoskeleton in high-permeability edema due to botulinum C2 toxin in perfused rabbit lungs. Am J Physiol-Lung Cell Mol Physiol. 1995;268(5):L753-L761. doi:10.1152/ajplung.1995.268.5.L753
Ermert L, Duncker HR, Bruckner H, et al. Ultrastructural changes of lung capillary endothelium in response to botulinum C2 toxin. J Appl Physiol. 1997;82(2):382-388. doi:10.1152/jappl.1997.82.2.382
Alexander SP, Kelly E, Mathie A, et al. The concise guide to PHARMACOLOGY 2021/22: Introduction and other protein targets. Br J Pharmacol. 2021;178(S1):S1-S26. doi:10.1111/bph.15540